{
  "symbol": "REGN",
  "year": 2024,
  "Period": "Q3",
  "report_type": "Q10",
  "metrics": {
    "mdna_sentiment": -0.2732,
    "outlook_sentiment": 0.1956,
    "forward_ratio": 1.0,
    "hedge_ratio": 0.473
  },
  "top_positive": [
    {
      "sent": "Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2024 2023 EYLEA 8 mg and EYLEA net product sales outside the United States $ 849.4 $ 847.1 Regeneron's share of collaboration profit from sales outside the United States $ 350.5 $ 346.9 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (16.6) (15.3) Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States $ 333.9 $ 331.6 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 39% 39% Roche Collaboration Revenue Roche distributes and records net product sales of Ronapreve outside the United States, and the parties share gross profits from sales.",
      "score": 0.989
    },
    {
      "sent": "Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2024 2023 EYLEA 8 mg and EYLEA net product sales outside the United States $ 849.4 $ 847.1 Regeneron's share of collaboration profit from sales outside the United States $ 350.5 $ 346.9 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (16.6) (15.3) Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States $ 333.9 $ 331.6 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 39% 39% Roche Collaboration Revenue Roche distributes and records net product sales of Ronapreve outside the United States, and the parties share gross profits from sales.",
      "score": 0.989
    },
    {
      "sent": "Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2024 2023 EYLEA 8 mg and EYLEA net product sales outside the United States $ 849.4 $ 847.1 Regeneron's share of collaboration profit from sales outside the United States $ 350.5 $ 346.9 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (16.6) (15.3) Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States $ 333.9 $ 331.6 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 39% 39% Roche Collaboration Revenue Roche distributes and records net product sales of Ronapreve outside the United States, and the parties share gross profits from sales.",
      "score": 0.989
    }
  ],
  "top_negative": [
    {
      "sent": "Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims.",
      "score": -0.9559
    },
    {
      "sent": "We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems.",
      "score": -0.9531
    },
    {
      "sent": "Further, we may be unable to pursue our research and development efforts if the relevant facility were to cease operations due to fire, climate change, natural disasters, acts of war or terrorism, or other disruptions.",
      "score": -0.9371
    }
  ],
  "forward_snippets": [
    "didates; \u2022 the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "(b) In collaboration with Sanofi (c) The Company is solely responsible for the development and commercialization of Praluent in the United States and Sanofi is responsible for the development and commercializa\nling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "Product is known as REGEN-COV in the United Sta\nguidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition.",
    "Intellia will lead the design of the editing methodology, we will lead the design of the targeted viral vector delivery approach, and the parties share costs equally.",
    "In April 2024, we acquired full development and commercialization rights to 2seventy bio's oncology and autoimmune preclinical and clinical stage cell therapy pipeline."
  ],
  "curated_text": "Symbol: REGN. Year: 2024. Period: Q3. ReportType: Q10. Section: Management Discussion and Analysis (MD&A). Key metrics include sentiment, forward outlook, and risk hedging.  Top positive sentences: Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2024 2023 EYLEA 8 mg and EYLEA net product sales outside the United States $ 849.4 $ 847.1 Regeneron's share of collaboration profit from sales outside the United States $ 350.5 $ 346.9 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (16.6) (15.3) Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States $ 333.9 $ 331.6 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 39% 39% Roche Collaboration Revenue Roche distributes and records net product sales of Ronapreve outside the United States, and the parties share gross profits from sales. Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2024 2023 EYLEA 8 mg and EYLEA net product sales outside the United States $ 849.4 $ 847.1 Regeneron's share of collaboration profit from sales outside the United States $ 350.5 $ 346.9 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (16.6) (15.3) Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States $ 333.9 $ 331.6 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 39% 39% Roche Collaboration Revenue Roche distributes and records net product sales of Ronapreve outside the United States, and the parties share gross profits from sales. Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States is summarized below: Three Months Ended March 31, (In millions) 2024 2023 EYLEA 8 mg and EYLEA net product sales outside the United States $ 849.4 $ 847.1 Regeneron's share of collaboration profit from sales outside the United States $ 350.5 $ 346.9 Reimbursement of development expenses incurred by Bayer in accordance with Regeneron's payment obligation (16.6) (15.3) Regeneron's share of profits in connection with commercialization of EYLEA 8 mg and EYLEA outside the United States $ 333.9 $ 331.6 Regeneron's share of profits as a percentage of EYLEA 8 mg and EYLEA net product sales outside the United States 39% 39% Roche Collaboration Revenue Roche distributes and records net product sales of Ronapreve outside the United States, and the parties share gross profits from sales. Top negative sentences: Other Regulatory and Litigation Risks \u2022 If the testing or use of our products harms people, or is perceived to harm them even when such harm is unrelated to our products, we could be subject to costly and damaging product liability claims. We and our collaborators would be unable to manufacture these materials if the relevant facility were to cease production due to regulatory requirements or actions, business interruptions, labor shortages or disputes, supply chain interruptions or constraints (including with respect to natural gas and other raw materials), contaminations, fire, climate change, natural disasters, acts of war or terrorism, or other problems. Further, we may be unable to pursue our research and development efforts if the relevant facility were to cease operations due to fire, climate change, natural disasters, acts of war or terrorism, or other disruptions. Forward-looking snippets: didates; \u2022 the ability of our collaborators, suppliers, or other third parties (as applicable) to perform manufacturing, filling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. (b) In collaboration with Sanofi (c) The Company is solely responsible for the development and commercialization of Praluent in the United States and Sanofi is responsible for the development and commercializa\nling, finishing, packaging, labeling, distribution, and other steps related to Regeneron's Products and Regeneron's Product Candidates; \u2022 the availability and extent of reimbursement of Regeneron's Products from third-party payors, including private payor healthcare and insurance programs, health maintenance organizations, pharmacy benefit management companies, and government programs such as Medicare and Medicaid; \u2022 coverage and reimbursement determinations by such payors and new policies and procedures adopted by such payors; \u2022 unanticipated expenses; \u2022 the costs of developing, producing, and selling products; our ability to meet any of our financial projections or guidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. Product is known as REGEN-COV in the United Sta\nguidance, including without limitation capital expenditures, and changes to the assumptions underlying those projections or guidance; \u2022 the potential for any license or collaboration agreement, including our agreements with Sanofi and Bayer (or their respective affiliated companies, as applicable), to be cancelled or terminated; \u2022 the impact of public health outbreaks, epidemics, or pandemics (such as the COVID-19 pandemic) on our business; and \u2022 risks associated with intellectual property of other parties and pending or future litigation relating thereto (including without limitation the patent litigation and other related proceedings described further in Note 11 to our Condensed Consolidated Financial Statements included in this report), other litigation and other proceedings and government investigations relating to the Company and/or its operations (including without limitation those described in Note 11 to our Condensed Consolidated Financial Statements included in this report), the ultimate outcome of any such proceedings and investigations, and the impact any of the foregoing may have on our business, prospects, operating results, and financial condition. Intellia will lead the design of the editing methodology, we will lead the design of the targeted viral vector delivery approach, and the parties share costs equally. In April 2024, we acquired full development and commercialization rights to 2seventy bio's oncology and autoimmune preclinical and clinical stage cell therapy pipeline."
}